Purnovate, Inc. – a subsidiary of Adial Pharmaceuticals, Inc. – has announced their collaboration with the Medical College of Wisconsin, a leading medical school, and Dr. John Auchampach, PhD, Professor and Vice Chair of the Department of Pharmacology and Toxicology. The collaboration aims to further evaluate the Company’s proprietary adenosine analogs as potential treatments for diabetes and non-alcoholic steatohepatitis (NASH).

The company is focused on developing novel molecules to target the adenosine receptors for the treatment of major unmet medical needs. Under the new agreement, Dr. Auchampach and his team will test Purnovate’s adenosine compounds in preclinical models. 

Dr. Julien Dimastromatteo, Purnovate’s Vice President, Research, commented, “We are honored to partner with the Medical College of Wisconsin and Dr. Auchampach, a leading researcher in the field of adenosine, purinergic pharmacology and G-Protein-Coupled receptors. Adenosine analogs have been studied extensively by Dr. Auchampach and others, demonstrating tremendous promise in animal models. However poor biodistribution of historical compounds, likely due to poor solubility, has limited their usefulness as human therapies. Our Purnovate adenosine analog compounds were specifically designed to overcome these solubility and biodistribution challenges, with strong supporting data thus far. As a result, we are encouraged by the therapeutic potential of these compounds and will work to rapidly identify a lead compound to bring forward as a drug candidate.”

The adenosine compounds are meant to provide a safe, oral therapy option to reduce overall body mass and liver fat content while restoring healthier glucose levels. The company believes their compounds could hold significant potential as an alternative therapy for diabetics, pre-diabetics, and overweight individuals.

Are you developing new technology for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.

Researchers at the University of Wisconsin, Baylor College of Medicine, Bayer AG, and the University of Oxford have discovered an alternative therapeutic option for the treatment of painful endometriosis without using surgery or hormones. Following a genetic study, these scientists have found a promising new non-hormonal target they intend to further investigate. It seems this target may allow treatment to address the inflammatory and pain components of the disease.

They designed and conducted genetic analyses on humans and rhesus macaques – two species which have spontaneously developed endometriosis – and uncovered the gene NPSR1 (neuropeptide S receptor 1) associated with the disease.

The endometrium is the inner lining of the uterine wall that builds up and sheds periodically during the reproductive lifespan in women. In women suffering from endometriosis, endometrium-like tissue grows outside the uterus leading to inflammation, intense abdominal pain usually associated with menstrual periods, and infertility.

Although the molecular causes of endometriosis are not known, heritability is estimated at about 50% indicating a strong genetic component. Current treatment options are hormone therapy and surgery with a dire need for non-hormonal therapeutics.

The scientists have worked towards therapeutic efficacy by inhibiting NPSR1 in mouse models. Inhibition was achieved using the small molecular inhibitor SHA 68R, and saw a successful reduction of abnormal infiltration of the endometrial tissue outside the uterus. If corroborated in nonhuman primate and human trials, this may lead to a non hormonal drug for endometriosis.

Are you developing new software for an existing application? Did you know your development work could be eligible for the R&D Tax Credit and you can receive up to 14% back on your expenses? Even if your development isn’t successful your work may still qualify for R&D credits (i.e. you don’t need to have a patent to qualify). To find out more, please contact a Swanson Reed R&D Specialist today or check out our free online eligibility test.

Who We Are:

Swanson Reed is one of the U.S.’ largest Specialist R&D tax advisory firms. We manage all facets of the R&D tax credit program, from claim preparation and audit compliance to claim disputes.

Swanson Reed regularly hosts free webinars and provides free IRS CE and CPE credits for CPAs. For more information please visit us at www.swansonreed.com/webinars or contact your usual Swanson Reed representative.